Coadministration with strong CYP3A4/CYP3A5 inhibitors should be avoided where possible as they may reduce plasma clearance of<unk> .
Axitinib
Ceritinib
Abrocitinib
Upadacitinib
Sunitinib
Afatinib
Erdafitinib
Dacomitinib